HANOI, VIETNAM / ACCESS Newswire / April 14, 2025 / Together with world-renowned scientists including Prof. Joel F. Habener, ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat type 2 diabetes and obesity. The Biedenharn Museum and Gardens is hosting a ...

The following is a summary of “Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...